Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

First Rapid COVID-19 Antigen Test Gets Green Light

Executive Summary

In a potential game-changer in the ongoing fight to expand COVID-19 testing, the FDA has authorized a new kind of test that can be used by certain health care providers on-site to diagnose patients with the SARS-CoV-2 virus within minutes instead of days.

You may also be interested in...



Abbott Mass Distributes Rapid COVID-19 Tests, Offers App So Consumers Can Display Test Results

BinaxNOW rapid tests, the size of a credit card with no other equipment required, are sold directly to organizations at $5 each and an at-home version, with use guided through digital links, is available at $25 per test. It can be paired with NAVICA app, allowing consumers to display negative results through a temporary digital health certificate.

First COVID-19 At-Home Test That Doesn’t Require A Prescription Authorized By The FDA

Ellume Health’s COVID-19 Home Test isn’t just a relatively fast, accurate and easy-to-administer antigen diagnostic, but it’s also available over-the-counter, which greatly expands public access to such tests.

FDA: Rapid Antigen COVID-19 Tests At Risk For False Positives

An alert from the agency warns that the tests, which have become widely used for their speed and portability, carry a risk of false positives.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM007466

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel